<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03584893</url>
  </required_header>
  <id_info>
    <org_study_id>TR-CTX-001</org_study_id>
    <nct_id>NCT03584893</nct_id>
  </id_info>
  <brief_title>The Prevalence of CTX Disorder in Juvenile Cataract Cases in Turkey</brief_title>
  <acronym>GEN-EYE-I</acronym>
  <official_title>An Observational Study With Retrospective and Prospective Evaluations to Determine the Prevalence of Cerebrotendinous Xanthomatosis (CTX) Disorder in Juvenile Cataract Cases in Turkey</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TRPHARM</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Klinar CRO</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Düzen Laboratories Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>TRPHARM</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Epidemiologic observational study. Study will include two phases:

        1. Retrospective cross-sectional phase: At this stage of the study, retrospective
           screenings are carried out at study sites and all juvenile cataract cases are planned to
           be determined.

        2. Prospective phase: At this stage of the study, identified juvenile cataract cases as a
           result of retrospective screenings will be called to be invited to the sites and blood
           samples will be obtained for the cholestanol tests for the cases that have given
           Informed Consent.

      This observational study is designed in two phases; retrospective and prospective.
      Retrospective part includes screening the patient database and / or patient files at
      ophthalmology clinics participating in the study and identifying patients diagnosed with
      idiopathic juvenile cataracts. The data of patients with idiopathic juvenile cataracts will
      be reviewed and the data of the patients meeting the inclusion/exclusion criteria will be
      recorded. Once this phase is completed, the prospective phase of the study will start and the
      patients meeting the criteria will be invited to the site to participate in the study.
      Current data will be collected from the patients who agree to participate in the study and
      the clinical status of the patients will be evaluated according to the Mignarri index. In
      addition, blood will be obtained from all patients to diagnose CTX disease. Blood samples
      will be sent to Duzen Laboratories in Ankara and analyzed for cholestanol.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of juvenile cataract patients</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>Rate of juvenile cataract patients whose cholestanol test result is above threshold (3.75 mg/mL) and suspected CTX cases</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CTX history in family</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>The history of the disease will be assessed from the patient records and by interview</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of consanguineous marriage</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>Presence of consanguineous marriage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The frequency of the systemic findings</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>The frequency of the following systemic findings:
Tendon xanthomas
Chronic diarrhea
Prolonged neonatal jaundice
Early osteoporosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The frequency of the neurological symptoms</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>The frequency of the following neurological symptoms:
Cerebellar ataxia
Spastic paraparesis
Disruption of dentate nucleus signal detected by MRI
Intellectual disability
Psychiatric disorders
Epilepsy
Parkinson
Polyneuropathy</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Cerebrotendinous Xanthomatosis</condition>
  <arm_group>
    <arm_group_label>Epidemiologic observational study cohort</arm_group_label>
    <description>All patients over 1 year old diagnosed as idiopathic bilateral juvenile cataracts will be included in the study at the study sites.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sampling for Cholestanol Analysis</intervention_name>
    <description>Cholestanol analysis will be performed to see the Rate of juvenile cataract patients whose cholestanol test result is above threshold (3.75 mg/mL) and suspected CTX cases</description>
    <arm_group_label>Epidemiologic observational study cohort</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples will be sent to Duzen Laboratories in Ankara and analyzed for cholestanol.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients over 1 year old diagnosed as idiopathic bilateral juvenile cataracts will be
        included in the study at the study sites.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Providing the written informed consent form

          -  The patient should be diagnosed with idiopathic bilateral juvenile cataract

          -  Idiopathic bilateral juvenile cataract should be diagnosed while the patient must be
             take a day from one year (age)

          -  Syria ciziten who take their citizenship of Turkey could be enrolled to the study
             after signing of Informed Consent Form that translated to mother tongue by sworn
             translation office approved by ethic committee.

        Exclusion Criteria:

          -  If the patient has been diagnosed with CTX before his/her enrollment in the study,

          -  If the patient has been diagnosed with cataract due to any known reasons other than
             CTX including cataracts related to trauma,

          -  If the patient has been diagnosed with cataract due to cataractogenic treatments,

          -  If the patient has participated in an interventional clinical study within the last 30
             days,

          -  If the patient and/or his/her legal representative does not provide consent to
             participate in the study,

          -  If the patient will not be able to fulfill study requirements according to the
             investigator's opinion,

          -  If the patient had used cholic acid or chenodeoxycholic acid on or before the date of
             participation in the study

          -  Pregnancy and/or lactation

          -  Syria citizen that have not Turkey citizenship will not enroll to the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Serdar Altinel</last_name>
    <phone>00902123863149</phone>
    <email>serdar.altinel@trpharm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Adana State Hospital</name>
      <address>
        <city>Adana</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Çukurova University Medical Faculty Department of Ophtalmology</name>
      <address>
        <city>Adana</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ankara Training and Research Hospital</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ankara University Medical Faculty Department of Ophtalmology</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Başkent University School of Medicine</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dünya Göz Hospital</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hacettepe University Medical Faculty Department of Ophtalmology</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Health Sciences University Ankara State Hospital</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>SBU Gülhane Training and Research Hospital</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ulucanlar Göz Training Hospital</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Akdeniz University Medical Faculty Department of Ophtalmology</name>
      <address>
        <city>Antalya</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bursa Yüksek İhtisas Training and Research Hospital</name>
      <address>
        <city>Bursa</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uludağ University Medical Faculty Department of Ophtalmology</name>
      <address>
        <city>Bursa</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Dicle University School of Medicine</name>
      <address>
        <city>Diyarbakır</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fırat University School of Medicine</name>
      <address>
        <city>Elazığ</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osmangazi University Medical Faculty Department of Ophtalmology</name>
      <address>
        <city>Eskişehir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gaziantep University Şahinbey Training and Research Hospital</name>
      <address>
        <city>Gaziantep</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>İstanbul Health Sciences University Kanuni Sultan Süleyman Training and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istanbul University Istanbul Medical Faculty Department of Ophtalmology</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marmara University Medical Faculty Department of Ophtalmology</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prof.Dr.N.Reşat Belger Beyoğlu Göz Training and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dokuz Eylül University Medical Faculty Department of Ophtalmology</name>
      <address>
        <city>İzmir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ege University Medical Faculty Department of Ophtalmology</name>
      <address>
        <city>İzmir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>İzmir Dr. Behcet Uz Child Diseases and Surgery Training and Research Hospital</name>
      <address>
        <city>İzmir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kayseri Training and Research Hospital</name>
      <address>
        <city>Kayseri</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>İnönü University School of Medicine</name>
      <address>
        <city>Malatya</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mersin University Medical Faculty Department of Ophtalmology</name>
      <address>
        <city>Mersin</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ondokuz Mayıs University School of Medicine</name>
      <address>
        <city>Samsun</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karadeniz Technical University School of Medicine</name>
      <address>
        <city>Trabzon</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Van 100. Yıl University Dursun Odabaş Medical Center</name>
      <address>
        <city>Van</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Harran University Research and Application Hospital</name>
      <address>
        <city>Şanlıurfa</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Clayton PT (2016) Disorders of Bile Acid Synthesis. In: Saudubray JM, Baumgartner MR, Walter J (eds) Inborn metabolic diseases: diagnosis and treatment, 6th ed. Springer-Verlag, Heidelberg, pp 465- 477</citation>
  </reference>
  <reference>
    <citation>Nie S, Chen G, Cao X, Zhang Y. Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management. Orphanet J Rare Dis. 2014 Nov 26;9:179. doi: 10.1186/s13023-014-0179-4. Review.</citation>
    <PMID>25424010</PMID>
  </reference>
  <reference>
    <citation>Federico A, Dotti MT, Gallus GN (2003) Cerebrotendinous Xanthomatosis. In: Pagon RA, Adam MP, Ardinger HH, et al. (eds) GeneReviews Seattle (WA): University of Washington, Seattle, 1993- 2017 (updated 2016 Apr 14)</citation>
  </reference>
  <reference>
    <citation>Fraidakis MJ. Psychiatric manifestations in cerebrotendinous xanthomatosis. Transl Psychiatry. 2013 Sep 3;3:e302. doi: 10.1038/tp.2013.76. Review.</citation>
    <PMID>24002088</PMID>
  </reference>
  <reference>
    <citation>Cruysberg JR, Wevers RA, Tolboom JJ. Juvenile cataract associated with chronic diarrhea in pediatric cerebrotendinous xanthomatosis. Am J Ophthalmol. 1991 Nov 15;112(5):606-7.</citation>
    <PMID>1951610</PMID>
  </reference>
  <reference>
    <citation>Mignarri A, Gallus GN, Dotti MT, Federico A. A suspicion index for early diagnosis and treatment of cerebrotendinous xanthomatosis. J Inherit Metab Dis. 2014 May;37(3):421-9. doi: 10.1007/s10545-013-9674-3. Epub 2014 Jan 18.</citation>
    <PMID>24442603</PMID>
  </reference>
  <reference>
    <citation>Verrips A, Hoefsloot LH, Steenbergen GC, Theelen JP, Wevers RA, Gabreëls FJ, van Engelen BG, van den Heuvel LP. Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis. Brain. 2000 May;123 ( Pt 5):908-19.</citation>
    <PMID>10775536</PMID>
  </reference>
  <reference>
    <citation>Salen G, Steiner RD. Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX). J Inherit Metab Dis. 2017 Nov;40(6):771-781. doi: 10.1007/s10545-017-0093-8. Epub 2017 Oct 4. Review.</citation>
    <PMID>28980151</PMID>
  </reference>
  <reference>
    <citation>Cali JJ, Hsieh CL, Francke U, Russell DW. Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J Biol Chem. 1991 Apr 25;266(12):7779-83.</citation>
    <PMID>2019602</PMID>
  </reference>
  <reference>
    <citation>Yahalom G, Tsabari R, Molshatzki N, Ephraty L, Cohen H, Hassin-Baer S. Neurological outcome in cerebrotendinous xanthomatosis treated with chenodeoxycholic acid: early versus late diagnosis. Clin Neuropharmacol. 2013 May-Jun;36(3):78-83. doi: 10.1097/WNF.0b013e318288076a.</citation>
    <PMID>23673909</PMID>
  </reference>
  <reference>
    <citation>Khan AO, Aldahmesh MA, Mohamed JY, Alkuraya FS. Juvenile cataract morphology in 3 siblings not yet diagnosed with cerebrotendinous xanthomatosis. Ophthalmology. 2013 May;120(5):956-60. doi: 10.1016/j.ophtha.2012.10.032. Epub 2013 Jan 31.</citation>
    <PMID>23375591</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 19, 2018</study_first_submitted>
  <study_first_submitted_qc>July 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2018</study_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Juvenile Cataract</keyword>
  <keyword>CTX</keyword>
  <keyword>Diarrhea</keyword>
  <keyword>Neonatal Jaundice</keyword>
  <keyword>Xanthoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Xanthomatosis, Cerebrotendinous</mesh_term>
    <mesh_term>Xanthomatosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

